MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.

Journal of Clinical Pharmacy and Therapeutics 2018 December 2018 [Link] Mense ES, Smit AAJ, Crul M, Franssen EJF Abstract WHAT IS KNOWN AND OBJECTIVE: The use of cisplatin in the treatment of lung carcinoma is limited by nephrotoxicity. The aim of this study was to determine whether the incidence of nephrotoxicity in patients with lung […]

Comments Off on The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.

Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.

Journal of Thoracic and Cardiovascular Surgery 2019 January [Link] Hashimoto M, Takeuchi J, Takuwa T, Kuroda A, Nakamura A, Nakamichi T, Matsumoto S, Kondo N, Nakano T, Morimoto T, Hasegawa S Abstract OBJECTIVES: Definitive diagnosis of the T-component is sometimes challenging in malignant pleural mesothelioma (MPM). Pleural thickness has been reported to be a prognostic […]

Comments Off on Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.

Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.

Molecules 2018 November 29 [Link] Izquierdo-Sánchez V, Muñiz-Hernández S, Vázquez-Becerra H, Pacheco-Yepez J, Romero-Piña ME, Arrieta O, Medina LA Abstract Malignant pleural mesothelioma (MPM) is the most common tumor of the pulmonary pleura. It is a rare and aggressive malignancy, generally associated with continuous occupational exposure to asbestos. Only a multimodal-approach to treatment, based on […]

Comments Off on Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.

Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

The Journal of Thoracic and Cardiovascular Surgery 2018 October 22 [] Verma V, Ahern CA, Berlind CG, Lindsay WD, Grover S, Friedberg JS, Simone CB Abstract OBJECTIVES: There are 2 main treatment paradigms recognized by the National Comprehensive Cancer Network for resectable malignant pleural mesothelioma (MPM): induction chemotherapy followed by resection (IC/R), and up-front resection […]

Comments Off on Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).

Translational Lung Cancer Research 2018 October [Link] Raskin J, Surmont V, Cornelissen R, Baas P, van Schil PEY, van Meerbeeck JP Abstract Radical multimodality treatment for malignant pleural mesothelioma (MPM) is controversial, with intense debate (but lack of data) about which surgical procedure to perform [extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD)], if any. In order […]

Comments Off on A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).

Update on the management of malignant peritoneal mesothelioma.

Translational Lung Cancer Research 2018 October [Link] Sugarbaker PH Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease whose natural history is confined to the peritoneal space. Systemic chemotherapy has little impact on survival of patients with MPM. A surgical procedure with a goal of resection of all visible evidence of disease, called cytoreductive surgery […]

Comments Off on Update on the management of malignant peritoneal mesothelioma.

Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Lung Cancer 2018 November [Link] Rosskamp M, Macq G, Nackaerts K, Praet M, Van Eycken L, Van Meerbeeck JP, De Schutter H Abstract OBJECTIVES: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, for which treatment is often limited to palliative combination chemotherapy. Multimodality-therapy, including radical surgery, is largely restricted to clinical trials, leaving […]

Comments Off on Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.

International Journal of Molecular Science 2018 November 10 [Link] Mungo E, Bergandi L, Salaroglio IC, Doublier S Abstract Emerging evidence supports the idea that a dysfunction in cell metabolism could sustain a resistant phenotype in cancer cells. As the success of chemotherapeutic agents is often questioned by the occurrence of multidrug resistance (MDR), a multiple […]

Comments Off on Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.

Multimodality treatment of malignant pleural mesothelioma.

F1000Research 2018 October 22 [Link] Berzenji L, Van Schil P Abstract Malignant pleural mesothelioma (MPM) is a rare disease of the pleura and is largely related to asbestos exposure. Despite recent advancements in technologies and a greater understanding of the disease, the prognosis of MPM remains poor; the median overall survival rate is about 6 […]

Comments Off on Multimodality treatment of malignant pleural mesothelioma.

Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.

Medicine 2018 November [Link] Du Z, Yu Y, Wu D, Zhang G, Wang Y, He L, Meng R Abstract RATIONALE: Malignant Pleural Mesothelioma (MPM) is rare cancer and has a poor prognosis with resistance to chemotherapy or radiotherapy. Until now there is no standard third-line treatment for patients who have failed second-line therapy. PATIENT CONCERNS: […]

Comments Off on Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.